Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACUVUE THERAVISION WITH KETOTIFEN vs ALBALON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.
FDA-approved for the prevention and treatment of ocular itching associated with allergic conjunctivitis
FDA-approved: Relief of redness and itching of the eye due to minor eye irritations (e.g., smoke, dust, wind, swimming, or wearing contact lenses).,Off-label: Treatment of allergic conjunctivitis symptoms (as an adjunct).
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life is 4-6 hours; clinically, dosing every 6-8 hours is recommended, with adjustments in renal impairment
Not significantly metabolized in the eye; systemic absorption is minimal. After systemic absorption, it is metabolized primarily via glucuronidation and oxidation, with a half-life of approximately 12 hours.
Primarily metabolized in the liver via oxidative deamination by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary/fecal elimination (10-15%)
99% (primarily albumin and alpha-1-acid glycoprotein).
Approximately 99% bound to serum albumin and alpha-1-acid glycoprotein
2.4 L/kg (high tissue distribution, including ocular tissues).
0.5-0.8 L/kg, indicating distribution into total body water with moderate tissue binding
Ocular topical: ~0.1% systemic; oral: 70% (not relevant for contact lens application).
Oral: 60-70% due to first-pass metabolism; Ophthalmic: negligible systemic absorption (<1%)
No dosage adjustment required based on renal function; systemic absorption is minimal.
No dosage adjustment required; systemic absorption minimal.
No dosage adjustment required based on hepatic function; systemic absorption is minimal.
No dosage adjustment required; not studied in hepatic impairment.
Safety and efficacy in pediatric patients below 3 years of age have not been established. For children 3 years and older, administer one drop in each affected eye twice daily.
Children ≥3 years: same as adult dosing; children <3 years: safety and efficacy not established.
No specific dosage adjustment is required for elderly patients; use same dosing as for adults.
No specific adjustment; use with caution due to possible increased sensitivity to anticholinergic effects.
None
No FDA black box warning.
For topical ophthalmic use only; not for injection.,Contains benzalkonium chloride; soft contact lens wearers should remove lenses before application and wait at least 10 minutes before reinserting.,May cause transient stinging or burning upon instillation.,Use with caution in patients with known hypersensitivity to any component.
Use with caution in patients with cardiovascular disease (e.g., hypertension, arrhythmias) or hyperthyroidism due to systemic absorption.,Prolonged use may lead to rebound congestion (rhinitis medicamentosa) if used intranasally; ocular overuse may cause reactive hyperemia.,Avoid in patients with narrow-angle glaucoma (risk of angle closure).,Monitor for systemic effects (e.g., dizziness, headache, palpitations).
Hypersensitivity to ketotifen or any component of the product.
Hypersensitivity to naphazoline or any component of the formulation.,Narrow-angle glaucoma (absolute contraindication).,Patients with severe cardiovascular disease (e.g., uncontrolled hypertension, coronary insufficiency).,Concomitant use with MAO inhibitors or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis).
None reported.
No specific food interactions; however, avoid alcohol as it may exacerbate ocular irritation or dizziness.
Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenicity at doses up to 50 mg/kg/day orally. Risk to fetus is considered low when used topically as directed.
AUX: Category C. Naphazoline is an imidazoline sympathomimetic with potential for vasoconstriction; systemic absorption may reduce uterine blood flow. First trimester: limited human data; animal studies not evaluated for malformations. Second/third trimester: possible fetal hypoxia due to vasoconstriction; avoid use near term due to risk of neonatal tachycardia, hypertension, and irritability.
Ketotifen is excreted in human milk following oral administration; however, systemic absorption from ophthalmic use is negligible. M/P ratio not established for ophthalmic route. Consider benefit vs risk; caution in breastfeeding mothers.
No human data on excretion in breast milk. M/P ratio unknown. Naphazoline likely passes into milk due to low molecular weight; risk of infant vasoconstrictive effects if absorbed. Use with caution; avoid prolonged or high-dose use while breastfeeding.
No dosage adjustment required. Use as directed; pharmacokinetic changes in pregnancy are not significant for topical ophthalmic route.
No dose adjustment recommended for topical ophthalmic use. Systemic absorption is negligible; however, if systemic effects occur, reduce frequency. Pregnancy may alter ocular pharmacokinetics, but no specific adjustment data available.
Ketotifen is a mast cell stabilizer and antihistamine; contact lens must be removed before instillation and may be reinserted after 10 minutes. Do not use while wearing contact lenses. Advise patient to wait at least 5 minutes between different eye drops. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
ALBALON (naphazoline/pheniramine) ophthalmic solution: Use with caution in patients with cardiovascular disease or hypertension due to naphazoline's alpha-adrenergic effects; limit use to 3-4 days to avoid rebound conjunctival hyperemia; do not use in patients with narrow-angle glaucoma; remove contact lenses before instillation and wait 15 minutes before reinserting.
Remove contact lenses before using the drops and wait at least 10 minutes before reinserting.,Wash hands before use. Do not touch the dropper tip to any surface, including the eye.,Do not use if the solution changes color or becomes cloudy.,Use exactly as prescribed; do not use more often than directed.,If you miss a dose, use it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.,Contact your doctor if you experience eye pain, vision changes, or if symptoms persist or worsen.
Do not use while wearing soft contact lenses; remove lenses before using and wait at least 15 minutes before reinserting.,Avoid touching the dropper tip to any surface to prevent contamination.,Do not use more than 4 times daily or for longer than 72 hours without consulting a doctor; overuse can cause worsening redness.,Temporary stinging or blurred vision may occur upon instillation; do not drive until vision clears.,Seek medical attention if eye pain, vision changes, or persistent redness occur.
"Lisdexamfetamine, a prodrug of dextroamphetamine, increases central nervous system (CNS) arousal via dopamine and norepinephrine release, counteracting the sedative effects of ketotifen, a mast cell stabilizer with histamine H1-receptor antagonism and CNS depressant properties. The interaction results in reduced sedative efficacy of ketotifen, potentially affecting therapeutic outcomes in allergic conditions where sedation is beneficial, such as severe pruritus or urticaria. Clinically, patients may experience decreased drowsiness or sleepiness, which could be undesirable if ketotifen is prescribed specifically for its soporific effects."
"Pseudoephedrine, a sympathomimetic amine, exerts central nervous system (CNS) stimulant effects by indirectly activating adrenergic receptors, which can counteract the sedative properties of ketotifen, a histamine H1-receptor antagonist with mast cell stabilizing activity. This pharmacodynamic antagonism may reduce the therapeutic efficacy of ketotifen in managing allergic conditions, particularly its ability to cause drowsiness as a side effect. Clinically, patients may experience diminished sedation, potentially leading to decreased compliance or altered therapeutic outcomes in conditions where sedation is beneficial."
"Hydroxyamphetamine, an indirect-acting sympathomimetic amine, stimulates the release of norepinephrine from presynaptic nerve terminals, leading to activation of alpha- and beta-adrenergic receptors. This produces central nervous system (CNS) stimulation that may oppose the sedative effects of ketotifen, a histamine H1-receptor antagonist with sedative properties. Consequently, coadministration may result in reduced efficacy of ketotifen for sedation or sleep induction, potentially compromising its therapeutic benefit in conditions requiring CNS depression (e.g., allergic rhinitis, urticaria)."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACUVUE THERAVISION WITH KETOTIFEN vs ALBALON, answered by our medical review team.
ACUVUE THERAVISION WITH KETOTIFEN is a Antihistamine / Mast Cell Stabilizer that works by Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.. ALBALON is a Ophthalmic Antihistamine/Decongestant that works by Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACUVUE THERAVISION WITH KETOTIFEN and ALBALON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACUVUE THERAVISION WITH KETOTIFEN is: One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.. The standard adult dose of ALBALON is: 1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACUVUE THERAVISION WITH KETOTIFEN and ALBALON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACUVUE THERAVISION WITH KETOTIFEN is classified as Category A/B. Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showe. ALBALON is classified as Category C. AUX: Category C. Naphazoline is an imidazoline sympathomimetic with potential for vasoconstriction; systemic absorption may reduce uterine blood flow. First trimester: limited huma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.